Results 41 to 50 of about 112,411 (265)

How has the COVID‐19 pandemic affected eczema self‐management and help seeking? A qualitative interview study with young people and parents/carers of children with eczema

Skin Health and Disease, 2021
Background Eczema can have a considerable impact on quality of life. Treatments can improve this, but management is complex. Barriers to eczema self‐management may be impacted upon by environmental context, such as the COVID‐19 pandemic.
M. Steele, L. Howells, M. Santer, K. Sivyer, S. Lawton, A. Roberts, E. Teasdale, I. Muller, K. Greenwell   +8 more
doaj   +1 more source

Antibiotics in the first week of life are not associated with functional gastrointestinal disorders at 9–12 years of age

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Dysbiosis due to early‐life antibiotics may contribute to the development of functional gastrointestinal disorders (FGIDs). This follow‐up study of a birth cohort primarily investigates the association between antibiotic treatment in the first week of life and the presence of FGIDs at 9–12 years.
Nora C. Carpay, Kim Kamphorst, Ruurd M. van Elburg, Arine M. Vlieger   +3 more
wiley   +1 more source

Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

JPGN Reports, EarlyView.
Abstract Objectives Eosinophilic esophagitis (EoE) is a type 2 cytokine‐mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL‐4 and IL‐13 signaling, which are key inflammatory mediators in EoE and other allergic disorders.
Sindhura Kasturi, Tanaz Danialifar, Thirumazhisai Gunasekaran, Nick Shillingford, Paul Zamiara, Vrinda Bhardwaj, Melinda Braskett   +6 more
wiley   +1 more source

Eczema phenotypes and risk of allergic and respiratory conditions in school age children

Clinical and Translational Allergy, 2020
Background Eczema phenotypes based on eczema onset and persistence might better identify groups prone to allergic and respiratory conditions than a binary definition of eczema.
Chen Hu, Tamar Nijsten, Evelien R. van Meel, Nicole S. Erler, Christophe Piketty, Nicolette W. de Jong, Suzanne G. M. A. Pasmans, Johan C. de Jongste, Liesbeth Duijts   +8 more
doaj   +1 more source

Case series: Joubert syndrome and eosinophilic esophagitis

JPGN Reports, EarlyView.
Abstract Joubert syndrome (JS) is a rare genetic disorder characterized by developmental abnormalities, particularly in the brainstem and cerebellar vermis, alongside multisystem manifestations such as kidney and liver anomalies, polydactyly, cleft lip or palate, and tongue defects.
Jonathon Schening, Stephanie Leon‐Paredes, Eric Chiou, Vibha Szafron, Anthony Olive, Sara Anvari   +5 more
wiley   +1 more source

Patient and caregiver motivators and barriers to eczema clinical trial participation: Analysis of survey data

Skin Health and Disease
Background Eczema clinical trials (CTs) are increasing in number, yet participation across the eczema community is low. Little is known about patient characteristics and views on motivators and barriers to CT participation (CTP).
Michael Evan Jacobson, Isabelle J. Thibau, Wenelia Baghoomian, Emile Latour, Ajai Kastala, Allison R. Loiselle, Eric Lawrence Simpson, Wendy Smith Begolka   +7 more
doaj   +1 more source

Genetic analysis of insect bite hypersensitivity (summer eczema) in Icelandic horses

Animal, 2008
There is a lack of knowledge about the genetic background of eczema due to insect bite hypersensitivity, also called summer eczema, in horses. The condition is known in several horse breeds and countries and it causes reduced welfare of the horse and ...
S. Eriksson, K. Grandinson, W.F. Fikse, L. Lindberg, S. Mikko, H. Broström, R. Frey, M. Sundquist, G. Lindgren   +8 more
doaj   +1 more source

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo   +2 more
wiley   +1 more source

Atopic eczema [PDF]

Clinical Medicine, 2016
Atopic eczema is an itchy inflammatory skin disease with a chronic relapsing-remitting course; it has increased in prevalence in recent decades and now affects up to 25% of school-aged children in the developed world and up to 10% of adults. Recent advances in understanding the aetiology of eczema have focused interest on skin barrier dysfunction as a ...
openaire   +3 more sources

Prevalence and Burden of Somatic Symptom Disorder in Atopic Dermatitis and Chronic Pruritus—The Persistent Somatic Symptoms Across Diseases: Pruritus (SOMA.PRU) Study

JEADV Clinical Practice, EarlyView.
In adults with atopic dermatitis and chronic pruritus, the mental comorbidity of Somatic Symptom Disorder is associated with higher average and worst pruritus intensity, higher psychological distress and lower quality of life. Additionally, there were nonsignificant changes in cutaneous nerve fiber densities in skin biopsies.
Stefan M. Kahnert, Ansgar Koechel, Gina L. Frank, Svenja Royeck, Claudia Zeidler, Felix Witte, Christian Mess, Konstantin Agelopoulos, Volker Huck, Bernd Löwe, Rupert Conrad, Gudrun Schneider, Stefan W. Schneider, Sonja Ständer   +13 more
wiley   +1 more source